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Objective: Questions remain regarding the optimal use of bone-targeted agents in patients with
metastatic bone disease. The purpose of this study was to assess current clinical practice regarding the
use and administration of bone-targeted agents by Canadian oncologists in patients with metastatic
breast and prostate cancer.
Methods: A survey was designed to explore; bone-targeted agent use in metastatic bone disease,
variability in the choice and the frequency of administration of these agents. Opinions were sought on
potential outcomes for future trials.
Results: A total of 193 clinicians were contacted and 90 completed our survey (response rate 49% after
adjustment for inactivity). Survey respondents were medical oncologists (71.1%), radiation oncologists (21.1%)
and urologists (7.8%). The ﬁndings suggest that once bone-targeted agents are started they
are rarely discontinued. More agents are used in breast cancer than in prostate cancer. There was considerable
interest in performing studies of de-escalated therapy in both breast and prostate cancer. Physicians requested
(86%) that the primary study endpoint be the occurrence of skeletal related events and not biomarker driven.
Conclusions: Despite clinical practice guidelines and widespread use, signiﬁcant areas of clinical equipoise with
respect to use of bone-targeted agents exist. Findings from this survey suggest that physicians are interested in
de-escalated therapy for both breast and prostate patients. However, the use of multiple agents in breast cancer
and the desire for skeletal related events to be the primary endpoint means that very large randomized studies
will be required.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Despite the widespread use of bone-targeted therapies such as
bisphosphonates (e.g. zoledronate, pamidronate, clodronate) or
receptor activator of nuclear factor kappa-B ligand (RANKL)
antibodies (i.e. denosumab) in patients with metastatic bone
disease, many questions remain about their optimal use [1,2].
One question in particular pertains to identiﬁcation of the optimal
dosing frequency [3]. Bone-targeted agents are usually given
every 3–4 weeks, a dosing interval that is based predominantly
on their clinical development as an add-on treatment to standard. This is an open access article und
, The Ottawa Hospital Cancer
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).anti-cancer therapies such as chemotherapy [4], along with
data derived from the treatment of hypercalcemia from malig-
nancy [5–7].
This “one size ﬁts all” approach to the dosing intervals [8] is
sub-optimal however, as it ignores the long half-life of these
agents in bone [9] and the substantial variability in individual
patient risk of skeletal related events (SREs) [10]. Given the
modest magnitude of absolute beneﬁt of bone-targeted agents
on skeletal related event reductions, [2] it is important to inves-
tigate whether to not less frequent administration could affect the
efﬁcacy of these agents. This would not only result in reduced
ﬁnancial costs to both the patient and to the health care system,
but would also likely reduce drug-associated toxicity. The latter is
particularly important as toxicity of these agents has been shown
to be related to both the potency and the cumulative dose of the
bone-targeted agent [11].er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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frequencies of administration of these agents in metastatic breast
cancer patients [12,13] and others are still on going [17]. Despite
this, the results of the published trials would suggest that there is
still a need for larger deﬁnitive studies. In addition, we are not
aware of any similar studies planned for prostate cancer where
again the beneﬁts of bone-targeted agents in reducing SREs are
likely even more modest than that seen in breast cancer patients.
We are however aware of considerable variability in clinical
practice, not only between cancer centers, but also within centers
with respect to a number of questions around optimal use of bone-
targeted agents, despite various clinical practice guidelines [3].
Before contemplating a trial to formally assess the feasibility
of de-escalated bone-targeted treatment in both prostate and
breast cancer patients, we wished to conduct a survey of potential
collaborating physicians at Canadian hospitals regarding their
current clinical practice in these populations and their views on
this matter to assist with design of future trials. In particular, we
hoped a survey would help establish current standards of care, the
extent of clinical equipoise with respect to de-escalation, physician
comfort with entering patients on such a trial, and ﬁnally, what
the most important outcomes and related effect sizes might be
for clinicians in order to establish the comparability of these
approaches to treatment.2. Methods
2.1. Questionnaire design
The survey was designed by the authors through three rounds
of question development and reﬁnement, and consists of three
components. The ﬁrst component was devised to collect pertinent
demographic information of the population of respondents, as
well as to determine what proportion amongst them use bone-
targeted agents to treat their patients. The second component was
designed to collect information from those respondents who
prescribe bone-targeted agents with regard to intended beneﬁts
from bone-targeted agent use, scenarios in which they prescribe
bone-targeted agents, and choice of agent for their patients in
order to gain an understanding of current Canadian clinical
practice. In the third component, respondents were presented
with a series of questions related to the design of a future clinical
trial geared toward studying the clinical beneﬁts of de-escalated
therapy, with topics of interest including outcome selection and
patient inclusion criteria.2.2. Survey frame and implementation
A member of the authorship team (MC) has held a national
annual meeting related to the study of bone in oncology patients
since 2005, and participants from past years' meetings were
considered an accessible, representative, and appropriate group
to approach as a population for this survey [3]. A list of all
participants' email addresses was compiled, and these individuals
were then sent a link via electronic mail inviting them to
participate in the survey. The survey was designed and imple-
mented using the online tool www.FluidSurveys.com. The survey
was initiated at the start of July 2012 and remained open until
September 1, 2012. Two reminder notices were sent to participants
in July and August of 2012. Local research ethics board approval
was received before commencing the study. The survey questions
used in this study can be found in the online supplement.2.3. Data analysis
Electronic invites were sent to a total of 193 clinicians, and
a total of 90 invitees responded; 11 of the email invites were
associated repeatedly with automatic out of ofﬁce responses, and
were thus excluded from the denominator (survey response
rate¼49.5%). All measures of respondent characteristics including
profession, type of center for clinical practice, province, popula-
tions treated (breast cancer, prostate cancer, or both), number of
new patients and follow up patients seen annually, and use of
bone-targeted agents were compiled and reported as proportions
of the total number of respondents. For summary statistics
calculated in relation to components two and three of the survey
as described above, a denominator of 66 respondents was used as
physicians not using bone-targeted agents in their practice were
not asked to respond to the questions associated with these
components. We tabulated proportions of different responses for
each question. Where relevant, we stratiﬁed ﬁndings according
to the type of patients treated by the respondents (i.e. breast
or prostate cancer; where respondents treated both populations,
they were included within both groups). Data were analyzed using
Microsoft Excel 2010 (Microsoft Corporation, Seattle, Washington).3. Results
3.1. Survey component 1: characteristics of the respondent
population
Physician demographics from the population of respondents
are shown in Table 1. The distribution of characteristics shows that
the majority work in teaching hospitals, consistently manage
moderate to large numbers of patients, and that 55.6% (50/90)
see at least one new patient per month, suggesting the population
is an experienced group of oncologists. Approximately two thirds
of the respondents were medical oncologists, with the remainder
consisting of radiation oncologists and urologists. Physicians were
located predominantly in Ontario (60%), Quebec (13.3%) and
Alberta (11.1%). Totals of 43, 26 and 18 respondents treated breast
cancer, prostate cancer, or both, respectively; 3 respondents failed
to indicate their specialty. Amongst the 90 respondents, 73.3% (43/
43 treating breast cancer patients, 12/26 treating prostate cancer
patients, and 11/18 treating both) indicated that use of bone-
targeted agents is a part of their clinical practice, and thus
continued on to complete component two of the survey.
3.2. Survey component 2: bone-targeted agent use in Canadian
practice
3.2.1. Rationale for bone-targeted agent use
Respondents were ﬁrst asked to describe the primary reasons
they provide bone-targeted agents to their patients, with the ability
to select multiple reasons as deemed relevant (see online question-
naire in supplementary data). Fig. 1 provides a quantitative summary
of the reasons that were reported. Most respondents primarily
provide bone-targeted agents to reduce fracture risk (95.45%), to
reduce risk of surgery to bone or radiotherapy (87.88%), to reduce
metastasis pain (89.39%), to improve quality of life (72.13%), to reduce
hypercalcaemia risk (71.21%), and to reduce risk of spinal compres-
sion (68.18%). Few do so based on beliefs that these agents will
improve progression-free survival (18.18%) or overall survival (4.55%).
Response proﬁles were generally consistent across sub-populations
of those treating breast cancer, prostate cancer, or both diseases
(Fig. 1).
To assess the situations in which bone-targeted treatment
might be prescribed, respondents were presented a series of ﬁve
Table 1
Summary of respondent population.
Characteristic Summary measure
Total # responders/Total # contacted 90/182 (49.5%)
Specialty
Medical oncologist 64 (71.11%)
Radiation oncologist 19 (21.11%)
Urologist 7 (7.78%)
Location of practice
Teaching hospital 74 (83.15%)
Community hospital 11 (12.36%)
Other (cancer center) 4 (4.43%)
Province of practice
Alberta 10 (11.11%)
British Columbia 5 (5.56%)
New Brunswick 1 (1.11%)
Newfoundland and Labrador 1 (1.11%)
Nova Scotia 7 (7.78%)
Ontario 53 (58.89%)
Prince Edward Island 1 (1.11%)
Quebec 12 (13.33%)
Clinical population treated
Breast cancer 43 (49.43%)
Prostate cancer 26 (29.89%)
Both 18 (20.69%)
Missing 3
# New breast cancer patients
1 per year 1 (1.11%)
1 per month 40 (44.94%)
1 per week 12 (13.48%)
Other 9 (10.11%)
I do not treat breast cancer 27 (30.34%)
How many breast cancer patients under your care at a given time?
o10 3 (3.33%)
10–25 21 (23.33%)
26–50 20 (22.22%)
More than 50 18 (20.00%)
Not applicable 28 (31.11%)
# New prostate cancer patients
1 per year 5 (5.75%)
1 per month 22 (25.29%)
1 per week 7 (8.05%)
Other 13 (14.94%)
I do not treat prostate cancer 40 (45.98%)
How many prostate cancer patients under your care at a given time?
o10 9 (10.00%)
10–25 18 (20.00%)
26–50 12 (13.33%)
More than 50 7 (7.78%)
Not applicable 44 (48.89%)
Do you routinely prescribe bone-targeted agents for patients with bone metastases from breast or prostate cancer?
Yes 66 (73.3%)
No 24 (26.7%)
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targeted agent to the patient in question. Fig. 2 summarizes the
related responses. For Scenario 1 the physician was asked, “For a
typical patient seen in your clinic with newly diagnosed bone
metastases, I would usually recommend a bone-targeted agent
even if this patient has little or no pain”. For the responding
clinicians 93.75% indicated they would recommend treatment in
patients with newly diagnosed bone metastases, even if there is
little to no pain present. For Scenario 2 clinicians were asked, “For
a typical patient seen in your clinic with newly diagnosed bone
metastases, I would usually recommend a bone-targeted agent
even if the metastases were blastic”. In this setting, 85.94% of
respondents indicated they would recommend treatment. Results
from Scenario 3 showed that approximately 60% of respondents
would still recommend bone-targeted therapy in patients whohave a prognosis of 6 months or less due to visceral metastases.
Data from Scenario 4 showed that only 28.13% of responding
clinicians would recommend treatment in patients who display
poor oral hygiene or who require considerable dental work.
Finally, in Scenario 5, amongst the 23 respondents managing
prostate cancer patients who use bone-targeted agents, 21.74%
indicated that they would only start therapy in conjunction with
chemotherapy. Three of the 90 respondents indicated regular
monitoring of patients with new bone metastases using biomar-
kers such as urinary N-telopeptide to assess response to treatment.3.2.2. Choice of bone-targeted agent and frequency of administration
Respondents were asked to comment on their choice of bone-
targeted agent. There were some differences in the bone-targeted
Fig. 1. Reasons for administration of bone targeted agents.
Fig. 2. Summary of respondent answers, scenarios 1–5. Summary of responses to Scenarios 1–5. ‘n’ Scenario 5 pertains only to respondents who use bone targeted agents to
treat prostate cancer patients (n¼23).
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(Fig. 3). Amongst respondents who treat breast cancer, pamidro-
nate was the agent most consistently used (52/61¼85.25%), while
denosumab (42/61¼68.85%), zoledronic acid (40/61¼65.57%)
and oral clodronate (31/61¼50.82%) had also been used to various
degree by large proportions of clinicians. Amongst respondents
who treat prostate cancer, zoledronic acid (20/23¼86.96%) and
denosumab (19/23¼82.61%) were both used.
For breast cancer patients, there was a variation in the
frequency of administration of bone targeted agents (Fig. 4). After
exclusion of two respondents with missing data for this question, a
total of 16/52 (30.77%) treat patients every 3–4 weeks from the
start, 8/52 (15.38%) responded every 3–4 weeks unless there is afall in performance status, 1/52 (1.92%) indicated every 3–4 weeks
for 3 months before modifying to once every 3 months, 11/52
(21.15%) indicated every 3–4 weeks for a year before modifying to
once every 3 months, 11/52 (21.15%) indicated every 3–4 weeks for
2 years before modifying to once every 3 months. Finally, 5/52
(9.61%) respondents noted other scenarios, which relied upon
patients' SRE history, extent of disease, and presence of concurrent
chemotherapy. For prostate cancer patients, 8/23 (34.78%) treat
patients every 3–4 weeks from the start, 5/23 (21.74%) every 3–4
weeks unless there is a fall in performance status, 3/23 (13.04%)
indicated every 3–4 weeks for 3 months before modifying to once
every 3 months, 1/23 (4.35%) indicated every 3–4 weeks for a year
before modifying to once every 3 months. Finally, 3/23 (13.04%)
Fig. 3. Proportion of respondents indicating use of different bone-targeted agents to treat breast and prostate cancer patients.
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every 3 months, and 3/23 (13.04%) noted other frequencies.3.2.3. Cessation or modiﬁcation of bone-targeted therapies
Clinicians were asked how frequently they would stop therapy
once started. The answers showed that cessation was not com-
mon; 28/64 (43.75%) indicated never or o5% of the time, 21/64
(32.80%) between 5% and 25% of the time, 8/64 (12.5%) between
26% and 50% of the time, and 6/64 (9.4%) 450% of the time. This
trend was generally consistent amongst the sub-groups of those
treating breast cancer, prostate cancer, or both. Clinicians did not
feel that worsening of bone pain, the presence of radiographic
evidence of progression or the occurrence of an SRE while on a
bone-targeted agent was an indication to stop this therapy. Indeed,
the most common reasons for treatment cessation were; a marked
deterioration of performance status (57.81%), the occurrence of
intolerable side effects (18.75%) and progression of disease outside
the bone (4.7%). Other assorted reasons (18.75%) included; pre-
sence of renal failure, duration of treatment 41–2 years, rising
creatinine levels, and proximity to death.
3.3. Survey component 3: potential future trials of de-escalated
therapy
In the third survey component respondents were asked to
share their views regarding potential patient enrollment criteria,
clinical outcomes of interest and minimum clinically important
differences for these measures, to explore opinions regarding key
parameters for the planning of future trials. When presented with
several alternatives regarding potential patient populations that
could be studied, physicians were asked to assess whom they
would be comfortable enrolling into a randomized controlled trial.
The question around duration of prior bone-targeted agent
use prior to study randomization (i.e. 3 months vs. 1 year) did
not produce a majority decision. However, in a situation of clinical
equipoise the ﬁnding that 45.5% of respondents were comfortable
randomising those who have received 3 months of prior therapy
and 59.1% were comfortable with those who have received 1 year
treatment tells us that such trials are still very feasible.
Physicians were asked to rank order the potential primary
study outcomes for a clinical trial of de-escalated treatment from
the most to the least clinically meaningful. SRE was the measure
that was most commonly ranked to be most meaningful (57/66¼
86.4% of respondents), while pain (10.60%) and patient preference
(3.03%) were chosen much less frequently. Patient preference wasmost commonly ranked to be least meaningful (46/66¼69.7%).
When asked what between-group difference in the Brief Pain
Inventory (BPI) score would be an appropriate amount to suggest
equivalent effectiveness between groups, 22 (34.4%) suggested
1 point, 30 (46.9%) suggested 2 points, 6 (9.4%) suggested 3 points,
and 6 (9.4%) were not comfortable giving a response. When asked
what between-group difference in the number of SREs would
be an appropriate amount to suggest equivalent effectiveness
between groups, 17 (26.6%) suggested a null difference, 24
(37.5%) suggested a difference within 1 SRE, 16 (25%) suggested a
difference within 2 SREs, and 3 (4.7%) suggested within 3 SREs
(4 (6.3%) were not comfortable providing a response). While
designing a clinical trial to compare different frequencies of drug
administration should use expected differences in each outcome
based on prior trial results, it is important to also obtain feedback
on subjective evaluations and feedbacks from physicians who use
these agents. This type of feedback also helps ensure that the
results of such a trial will likely have a clinical impact on
patient care.4. Discussion
There is considerable interest in optimizing the frequency of
administration of bone-targeted agents as the current “one size ﬁts
all” approach is likely inefﬁcient, expensive, and there is reason to
believe that some patients may achieve equivalent beneﬁt and
improved safety with less frequent treatment administration. The
results of the two published trials, assessing reduced frequencies
of administration of these agents, would suggest there is still a
need for larger deﬁnitive studies [12,13]. In addition, we are not
aware of any similar studies planned for prostate cancer where
again the beneﬁts of bone-targeted agents in reducing SREs are
likely even more modest than that seen in breast cancer patients.
We are aware that physician surveys have been previously used
to assess; bisphosphonate use for bone pain [14], bisphosphonate
use in metastatic breast cancer patients [15] and radiotherapy use
for painful bone metastases [16] but are not aware of physician
surveys being used to help design trials of bone-targeted agents.
Given the need for larger deﬁnitive studies this survey was
designed to develop a greater understanding of the current clinical
practice at Canadian centers in terms of frequency of use of bone-
targeted agents and preferred choice of agent and frequency of
administration. It was also designed to explore the degree of
clinical equipoise which would underlie potential future trials of
de-escalated bone-targeted therapy in breast and prostate cancer
Fig. 4. Distribution of administration frequency of bone targeted agents, by indication. Based on n¼52 breast cancer respondents and n¼23 prostate cancer respondents.
Those respondents who treat both types of patients contributed data for each indication.
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trials was also explored. The results from this survey tell several
important aspects of current clinical practice that can be explored
in trials.
The ﬁrst component was devised to collect pertinent demo-
graphic information of the population of respondents, as well as to
determine what proportion amongst them that use bone-targeted
agents to treat their patients. Firstly, it is evident that bone-
targeted agents are commonly used for both breast and prostate
patients with metastatic bone disease. It is also clear that the
rationale for starting these agents are indeed based on practice
guidelines [18,19].
The second component was designed to gain an understanding
of current Canadian clinical practice by collecting information
from those respondents who prescribe bone-targeted agents.
Speciﬁcally we sought to collect information with regard to
intended beneﬁts from bone-targeted agent use, scenarios in
which they prescribe bone-targeted agents and their choice of
agent for their patients. From this part of the study it was clear
that the rationale for starting these agents was based on practice
guidelines [18,19]. Respondents primarily provide bone-targeted
agents to reduce the risk of skeletal related events and improve
pain control. Few felt that these agents had any effect on either
progression-free or overall survival. The choice of bone-targeted
agent reﬂected funding and therefore more agents were used in
breast cancer patients (pamidronate, clodronate, zoledronic acid
or denosumab) than in prostate cancer patients (zoledronic acid or
denosumab). Treatments are usually given every 3–4 weeks and
once started clinicians rarely stopped therapy. Also of interest was
the fact that few clinicians use biomarkers of bone turnover to
assess response to therapy. With respect to discontinuation of
bone-targeted therapy clinicians did not feel that worsening of
bone pain, the presence of radiographic evidence of progression or
the occurrence of an SRE while on a bone-targeted agent was an
indication to stop this therapy. Indeed, the most common reasons
for treatment cessation was a marked deterioration in patient
performance status.
In the third component, respondents were presented with a
series of questions related to the design of a future clinical trial
geared toward studying the clinical beneﬁts of de-escalated
therapy, with topics of interest including outcome selection and
patient inclusion criteria. With respect to potential future trials,given that once started these agents are rarely stopped, it would
appear that initiating a study of effect of drug cessation would be
extremely difﬁcult to do from a practical standpoint. It is also
evident that there is more variability in the choice of bone-
targeted agent in the treatment of breast cancer patients than in
prostate cancer, which is likely a reﬂection of differential funding
for these agents. This means that for a de-escalation trial to be
performed in breast cancer patients the design would need to
incorporate the use of different bone-targeted agents. The results
do however conﬁrm that physicians are very interested in de-
escalation trials and that they would consider de-escalating
therapy from every 3–4 weeks to 3 monthly therapy and entering
patients on such a study at anytime from 3 months to 2 years after
starting treatment. However, physicians do want the primary
study endpoint to be SRE [11] and not biomarker studies using
biomarkers of bone turnover as a surrogate for skeletal related
event risk [12]. Ultimately the results from our survey conﬁrms
that trials exploring de-escalated use of bone targeted agents are
wanted for both breast and prostate cancer and that ultimately
there will remain a need for further very large randomised trials
with skeletal related events as the primary endpoint.
There are limitations to the current study. As with all surveys,
there is an inherent bias in those that are contacted and in those
that respond. Obtaining 90 responses on this topic is clearly
important, however, the study would be strengthened by a greater
number of responses. In addition, the majority of respondent were
from the two most highly populated Provinces in Canada, however
70% were from Ontario and Quebec, representing around 66% of
the total Canadian population. As the respondents tend to have an
interest in cancer and bone health and the majority is based in
academic centers, there is a bias that the results of our study
provide greater insight into practice at an academic center, but
potentially less so in a broad scope of practice. However, it is
important to appreciate that, in Canada, most cancer care is
delivered in large centers and most anti-cancer drugs are funded
through central regulatory bodies with speciﬁc funding policies,
thus reducing variability. Another limitation of this type of survey
is that it might not necessarily reﬂect what physicians actually
prescribe. This is important as one study of “real world” bispho-
sphonate prescribing has suggested that different treatment
schedules may result in differences in skeletal morbidity [20].
This study was retrospective and funded by the manufacturer of
B. Hutton et al. / Journal of Bone Oncology 2 (2013) 77–83 83zoledronate and therefore does not replace the need for prospec-
tive randomised studies.5. Conclusions
We believe that our objectives of developing a sense of current
Canadian practice involving bone-targeted agents in patients with
metastatic bone disease and exploring methodological considera-
tions for future trials have been achieved. These data will provide
valuable information to guide future efforts regarding this area of
research.Conﬂict of Interest Statement
Mark Clemons has received honoraria for talks from Amgen
and Novartis.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.jbo.2013.03.001.References
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